Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (291)
  2. Journal Article (132)
  3. Research Letter (15)
  4. Review (6)
  5. Correspondence (3)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (448)
  2. Center for Hematologic Malignancies (448)
  3. Department of Medicine (448)
  4. Hematologic Malignancies, Division of (448)
  5. Survivorship Research (448)
  6. Hematology-Oncology Fellows (347)

More Groups

People
  1. Sergio Giralt (311)
  2. Michael Scordo (299)
  3. Miguel-Angel Perales (204)
  4. Sean Devlin (187)
  5. Heather Landau (164)
  6. Parastoo Dahi (163)

More People

Years
  1. 2025 (24)
  2. 2024 (72)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (156)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (22)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (178)
  2. Elsevier Inc. (143)
  3. Nature Publishing Group (33)
  4. American Society of Clinical Oncology (15)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (8)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transplant strategies in relapsed/refractory Hodgkin lymphoma
    Journal Article

    Shah, G. L.; Moskowitz, C. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Therapeutic anticoagulation in patients with primary brain tumors or secondary brain metastasis
    Journal Article

    Lin, R. J.; Green, D. L.; Shah, G. L.
    The Oncologist (2018)

    Fulltext@MSK | Save
  • Value-based care in hematopoietic cell transplantation and cellular therapy: Challenges and opportunities
    Journal Article

    Shah, G. L.; Majhail, N.; Khera, N.; Giralt, S.
    Current Hematologic Malignancy Reports (2018)

    Fulltext@MSK | Save
  • Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance
    Journal Article

    Palazzo, M.; Shah, G. L.; Copelan, O.; Seier, K.; Devlin, S. M.; Maloy, M.; Kenny, S.; Hassoun, H.; Korde, N. S.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Disease progression is main barrier to allogeneic hematopoietic stem cell transplantation (HCT) in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Preston, E. V.; Chinapen, S.; Borrill, T.; Davis, E.; Shaffer, B. C.; Tamari, R.; Jakubowski, A. A.; Perales, M. A.; Ponce, D. M.; Shah, G. L.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Analysis of cytomegalovirus (CMV) infections in the first 180 days in adult sero-positive cord blood transplantation (CBT) recipients reveals high infection rates and treatment burden
    Meeting Abstract

    Lau, C.; Politikos, I.; Devlin, S. M.; Jacob, A. G.; Maloy, M.; Naputo, K.; Afuye, A.; Bhatt, V.; Dahi, P. B.; Perales, M. A.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Rituximab use, immune reconstitution, and vaccination after ex-vivo CD34-selected myeloablative allogeneic hematopoietic cell transplantation (HCT)
    Meeting Abstract

    Preston, E. V.; Malard, F.; Seier, K.; Cho, C.; Devlin, S. M.; Maloy, M.; Borrill, T.; Palazzo, M.; Smith, K.; Maslak, P.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Early CMV reactivation adversely impacts blood counts recovery at 1 year post-transplant in recipients of CD34(+) selected graft
    Meeting Abstract

    Tamari, R.; Cho, C.; Hilden, P.; Maloy, M.; Borrill, T.; Politikos, I.; Papanicolaou, G. A.; Jakubowski, A. A.; Gyurkocza, B.; Shaffer, B. C.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (allo-HCT)
    Meeting Abstract

    Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Early fluid overload is a serious toxicity associated with an increased risk of non-relapse mortality after ex-vivo CD34-selected allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Rondon-Clavo, C.; Scordo, M.; Hilden, P.; Shah, G. L.; Cho, C.; Maloy, M.; Papadopoulos, E. B.; Jakubowski, A. A.; O'Reilly, R. J.; Gyurkocza, B.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save